Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views
In the latest quarter, 5 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Teva Pharmaceutical Indus and provided 12-month price targets. The average target is $21.0, accompanied by a high estimate of $23.00 and a low estimate of $20.00. Observing a 12.9% increase, the current average has risen from the previous average price target of $18.60.
Investigating Analyst Ratings: An Elaborate Study
The perception of Teva Pharmaceutical Indus by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Glen Santangelo | Jefferies | Raises | Buy | $23.00 | $19.00 |
| Balaji Prasad | Barclays | Raises | Overweight | $21.00 | $20.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $21.00 | $18.00 |
| David Amsellem | Piper Sandler | Raises | Overweight | $20.00 | $19.00 |
| Balaji Prasad | Barclays | Raises | Overweight | $20.00 | $17.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Teva Pharmaceutical Indus's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Teva Pharmaceutical Indus's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Teva Pharmaceutical Indus analyst ratings.
Delving into Teva Pharmaceutical Indus's Background
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
A Deep Dive into Teva Pharmaceutical Indus's Financials
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Teva Pharmaceutical Indus displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 4.29%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -3.64%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.88%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.32%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio stands notably higher than the industry average, reaching 2.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.